Quest Diagnostics is teaming up with France's national health agency to create an expanded database for breast and ovarian cancer gene research, allowing diagnostics outfits and labs to sift through a trove of genetic information to improve outcomes for patients.
Juno Therapeutics' in-development cancer immunotherapy notched a 91% complete remission rate in a small trial on children with a form of leukemia, an incremental victory for the company as it rolls into late-stage trials.
Alnylam's lead RNAi treatment continued to prevent nerve damage tied to a rare disease in an ongoing Phase II study, paving the path for late-stage development.
Icon Bioscience has brought to light data from its late-stage extended-release cataract treatment, which demonstrated a high level of efficacy while reducing inflammation after surgery.
Fierce 15 member Mersana Therapeutics, a developer of customizable next-generation antibody-drug conjugates, announced that its lead anticancer candidate showed promise in preclinical studies.
The Wall Street Journal has caught up with the Genervon controversy, recapping a series of events from the last few days that followed the big social media campaign to gain an instant approval for a new ALS drug based on the results of a 12-patient study. FierceBiotech readers will know already that the data were questioned by Steve Perrin, president and chief scientific officer of the ALS Therapy Development Institute, and that the FDA followed up a day later with an extraordinary challenge to Genervon to publish the data on a drug that the biotech has touted as a major advance for patients.
Eli Lilly's closely watched autoimmune treatment ixekizumab met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space.
Eli Lilly's closely watched autoimmune treatment met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space.
St. Jude Medical will buy portfolio company Spinal Modulation. The startup has submitted a PMA for its Axium Neurostimulator System to treat chronic pain. St. Jude will pay up to $175 million upfront with additional undisclosed payments upon FDA approval of the Axium system and with the achievement of undisclosed revenue targets.
A novel immuno-oncology treatment from Novartis and the University of Pennsylvania came through in an early safety study on patients with solid tumors, encouraging investigators and burnishing its potential.